Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

620 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study.
van de Putte LB, Rau R, Breedveld FC, Kalden JR, Malaise MG, van Riel PL, Schattenkirchner M, Emery P, Burmester GR, Zeidler H, Moutsopoulos HM, Beck K, Kupper H. van de Putte LB, et al. Among authors: breedveld fc. Ann Rheum Dis. 2003 Dec;62(12):1168-77. doi: 10.1136/ard.2003.009563. Ann Rheum Dis. 2003. PMID: 14644854 Free PMC article. Clinical Trial.
Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis.
Smolen JS, Breedveld FC, Burmester GR, Combe B, Emery P, Kalden JR, Klareskog L, Maini RN, Numo R, van De Putte LB, van Riel PL, Rodriguez-Valverde V. Smolen JS, et al. Among authors: breedveld fc. Ann Rheum Dis. 2000 Jul;59(7):504-5. doi: 10.1136/ard.59.7.504. Ann Rheum Dis. 2000. PMID: 10873957 Free PMC article. Review. No abstract available.
Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000).
Furst DE, Breedveld FC, Burmester GR, Crofford JJ, Emery P, Feldmann M, Kalden JR, Kavanaugh AF, Keystone EC, Klareskog LG, Lipsky PE, Maini RN, Russell AS, Scott DL, Smolen JS, Van de Putte LB, Visher TL, Weisman MH. Furst DE, et al. Among authors: breedveld fc. Ann Rheum Dis. 2000 Nov;59 Suppl 1(Suppl 1):i1-2. doi: 10.1136/ard.59.suppl_1.i1. Ann Rheum Dis. 2000. PMID: 11053077 Free PMC article. Review. No abstract available.
Infliximab in active early rheumatoid arthritis.
Breedveld FC, Emery P, Keystone E, Patel K, Furst DE, Kalden JR, St Clair EW, Weisman M, Smolen J, Lipsky PE, Maini RN. Breedveld FC, et al. Ann Rheum Dis. 2004 Feb;63(2):149-55. doi: 10.1136/ard.2003.013961. Ann Rheum Dis. 2004. PMID: 14722203 Free PMC article. Clinical Trial.
Advances in targeted therapies XI.
Breedveld FC, Kalden JR, Smolen JS. Breedveld FC, et al. Ann Rheum Dis. 2010 Jan;69 Suppl 1:i1. doi: 10.1136/ard.2009.120253. Ann Rheum Dis. 2010. PMID: 19995739 No abstract available.
An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status.
van der Bijl AE, Breedveld FC, Antoni CE, Kalden JR, Kary S, Burmester GR, Beckmann C, Unnebrink K, Kupper H. van der Bijl AE, et al. Among authors: breedveld fc. Clin Rheumatol. 2008 Aug;27(8):1021-8. doi: 10.1007/s10067-008-0866-4. Epub 2008 Mar 19. Clin Rheumatol. 2008. PMID: 18350329 Free PMC article. Clinical Trial.
Evidence for treating rheumatoid arthritis to target: results of a systematic literature search.
Schoels M, Knevel R, Aletaha D, Bijlsma JWJ, Breedveld FC, Boumpas DT, Burmester G, Combe B, Cutolo M, Dougados M, Emery P, van der Heijde D, Huizinga TWJ, Kalden J, Keystone EC, Kvien TK, Martin-Mola E, Montecucco C, de Wit M, Smolen JS. Schoels M, et al. Among authors: breedveld fc. Ann Rheum Dis. 2010 Apr;69(4):638-643. doi: 10.1136/ard.2009.123976. Ann Rheum Dis. 2010. PMID: 20237123 Free PMC article. Review.
620 results